Stay updated with breaking news from Boxed Warning. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
LUPKYNIS® achieved significantly earlier reductions in UPCR and significantly higher renal response rates in lupus nephritis patients with high proteinuria, compared to patients treated with... | June 20, 2023
The FDA has approved Columvi®® (glofitamab-gxbm) for the treatment of adult patients with R/R DLBCL after ≥2 or greater lines of systemic therapy.
/PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that two scientific posters detailing...
/PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) today announced the 20 incredible women entrepreneurs who will receive funding and...
Brixadi (buprenorphine) is approved for patients with moderate to severe OUD who are already taking or have initiated transmucosal buprenorphine.